Venetoclax plus CLAD/LDAC and aza for older AML patients

Results from Venetoclax Added to CLAD Combo for Older Patients w/ #AML | Tapan Kadia, MD | ASH 2023Подробнее

Venetoclax for elderly AML patientsПодробнее

Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 yearsПодробнее

Pevonedistat, venetoclax and azacitidine for older AML patientsПодробнее

Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)Подробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

The role of venetoclax in older patients with AMLПодробнее

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungalsПодробнее

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AMLПодробнее

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AMLПодробнее

Venetoclax combination therapies in AMLПодробнее

Acute Myeloid Leukemia: Debate on Standard of Care for Patients ≥ 60 YearsПодробнее

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Venetoclax plus low-dose cytarabine in untreated older AML patientsПодробнее

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”Подробнее

allo-SCT improves survival following venetoclax and azacitidine therapy in AMLПодробнее

Venetoclax plus azacitidine for higher-risk MDSПодробнее

IDH mutations in AML treated with venetoclaxПодробнее

CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trialПодробнее

Timing of response to venetoclax combination treatment in older patients with acute myeloid leuk...Подробнее